Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Belzutifan Earns Positive CHMP Opinion for VHL Disease–Associated Tumors, Advanced ccRCC

December 13th 2024

The EMA’s CHMP has recommended the approval of belzutifan monotherapy for patients with select VHL disease–associated cancers.

NDI-101150 Demonstrates Antitumor Activity, Safety in Heavily Pretreated RCC

December 3rd 2024

NDI-101150 monotherapy demonstrated antitumor activity and was well tolerated among patients with heavily pretreated renal cell carcinoma.

ALLO-316 Demonstrates Early Activity and Safety in Advanced CD70-Positive ccRCC

November 27th 2024

ALLO-316, a CD70-directed CAR T-cell therapy, demonstrated preliminary efficacy and safety in CD70-positive ccRCC.

Dr Singer on Toxicities Associated With First-Line IO/TKI Regimens in RCC

November 22nd 2024

Adam E. Singer, MD, PhD, discusses the safety profiles of immuno-oncology/TKI regimens in first-line renal cell carcinoma.

NMPA Approves Belzutifan for VHL in RCC, CNS Hemangioblastomas, or pNETs

November 22nd 2024

The NMPA has approved belzutifan for von Hippel-Lindau disease in RCC, CNS hemangioblastomas, or pNETs not requiring immediate surgery.

Kidney Cancer NCCN Guidelines Receive Major Updates, Prostate Cancer Adds Targeted Agents

November 21st 2024

Sandy Srinivas, MD, details updates from 2024 in the kidney and prostate cancer NCCN guidelines and agents/trials to look forward to in 2025.

Dr Biachi on the Evolving Role for Surgery in CRC

November 12th 2024

Tiago Biachi, MD, PhD, discusses the evolving role for surgery in colorectal cancer.

Post Hoc Analysis Reveals Potential Serum Glycoproteomic Biomarkers for Nivolumab/Cabozantinib in Advanced RCC

November 9th 2024

David A. Braun, MD, PhD, discusses the potential for protein glycosylation as a biomarker to predict nivolumab/cabozantinib responses in advanced RCC.

Dr Singer on the Efficacy of IO/TKI Doublets in Advanced RCC

November 9th 2024

Adam E. Singer, MD, PhD, discusses currently available combination treatment regimens for the first-line treatment of patients with renal cell carcinoma.

PD-L1, KIM-1 Expression Are Predictive of Outcomes With Adjuvant Nivolumab Alone, Plus Ipilimumab in ccRCC

November 8th 2024

The biomarker analysis of patients enrolled on part B of the CheckMate 914 trial explored the effects of PD-L1 and KIM-1 expression.

BT7480 Shows Preliminary Activity in Nectin-4+, CD137+ Tumors

November 7th 2024

The Nectin-4/CD137 Bicycle–targeted immune cell agonist BT7480 had antitumor activity in patients with Nectin-4– and CD137-expressing tumors.

Review Key Genitourinary Cancer Data From the 2024 ESMO Congress With Chandler Park, MD

November 6th 2024

Chandler Park, MD, talks through key updates in genitourinary cancer research from the 2024 ESMO Congress.

Dr Montero on Potential Advantages With STX-478 in PI3Kα-Mutant Solid Tumors

November 5th 2024

Alberto Montero, MD, MBA, CPHQ, discusses the mechanism of action and potential advantages of the mutant-selective PI3Kα inhibitor STX-478 in solid tumors.

Dr Westbrook on the Potential Use of ccRCC Therapies in Non-ccRCC

November 5th 2024

Thomas Westbrook, MD, discusses the investigation of approved ccRCC treatments in patients with non-ccRCC.

Casdatifan Demonstrates Durable Activity in Metastatic Clear Cell Renal Cell Carcinoma

November 1st 2024

Casdatifan was well tolerated and had durable clinical activity in patients with metastatic clear cell renal cell carcinoma.

The Top News From ESMO 2024: A Variety of Data Inform Solid Tumor Landscapes

November 1st 2024

This roundup includes exclusive insights from 23 clinicians and key data on the top abstracts coming out of the 2024 ESMO Annual Meeting.

FDA Grants Regenerative Medicine Advanced Therapy Designation to ALLO-316 in CD70+ Advanced RCC

October 31st 2024

The FDA has granted regenerative medicine advanced therapy to ALLO-316 in CD70-positive advanced or metastatic renal cell carcinoma.

New Computational Method Links One Mammal’s Striking Longevity and Resistance to Cancer With ‘Dark Genome’

October 30th 2024

A Roswell Park study reveals the evolutionary stability of the naked mole-rat’s genome, and implications for drug development.

Novel HPK1 Inhibitor NDI-101150 Shows Early Activity in RCC

October 29th 2024

Anita Scheuber, MD, PhD, details the mechanism of action of NDI-101150, early data seen with the agent, and next steps in the HPK1 inhibitor’s investigation.

Dr Tan on the Selection of IO-Based Combination Regimens in Advanced RCC

October 28th 2024

Alan Tan, MD, discusses long-term data guiding the selection of immuno-oncology combination regimens in advanced renal cell carcinoma.